Top

Published in:

01-12-2013 | Original Communication

Prominent psychiatric symptoms in patients with Parkinson’s disease and concomitant argyrophilic grain disease

Authors: O. Grau-Rivera, E. Gelpi, M. J. Rey, F. Valldeoriola, E. Tolosa, Y. Compta, M. J. Martí

Published in: Journal of Neurology | Issue 12/2013

Abstract

In Parkinson’s disease (PD), cognitive decline and psychiatric symptoms may occur and very often co-exist, eventually leading to PD-dementia. We report three patients with PD who presented striking psychiatric manifestations along with mild cognitive decline not progressing to dementia across the course of disease and in which postmortem neuropathological study revealed, besides alpha-synuclein inmunoreactive Lewy-body pathology, concomitant four-repeat tau positive argyrophilic grain pathology. We consider that argyrophilic grains might have modulated the clinical presentation of PD in these patients, being the main substrate of their prominent psychiatric symptoms in the absence of definite dementia.

Braak H, Braak E (1998) Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 105(8–9):801–819PubMedCrossRef

Pham CT, de Silva R, Haik S, Verny M, Sachet A, Forette B et al (2011) Tau-positive grains are constant in centenarians’ hippocampus. Neurobiol Aging 32(7):1296–1303PubMedCrossRef

Tolnay M, Schwietert M, Monsch AU, Staehelin HB, Langui D, Probst A (1997) Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathol 94(4):353–358PubMedCrossRef

Braak H, Braak E (1989) Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 15(1):13–26PubMedCrossRef

Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M et al (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61(6):547–556PubMed

Togo T, Isojima D, Akatsu H, Suzuki K, Uchikado H, Katsuse O et al (2005) Clinical features of argyrophilic grain disease: a retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry 13(12):1083–1091PubMed

Ikeda K, Akiyama H, Arai T, Matsushita M, Tsuchiya K, Miyazaki H (2000) Clinical aspects of argyrophilic grain disease. Clin Neuropathol 19(6):278–284PubMed

Martinez-Lage P, Munoz DG (1997) Prevalence and disease associations of argyrophilic grains of Braak. J Neuropathol Exp Neurol 56(2):157–164PubMedCrossRef

Kawashima T, Doh-ura K, Iwaki T (1999) Argyrophilic grains in late-onset Creutzfeldt-Jakob diseased brain. Pathol Int 49(5):369–373PubMedCrossRef

10.

Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN et al (2009) Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 23(3):229–233PubMedCrossRef

11.

Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y et al (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63(9):911–918PubMed

12.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211PubMedCrossRef

13.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11PubMed

14.

Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896PubMedCrossRef

15.

Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U et al (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 80(8):928–930PubMedCrossRef

16.

Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L (2010) The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 25(6):763–766PubMedCrossRef

17.

Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D et al (2010) A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 67(8):996–1001PubMedCrossRef

18.

Lee AH, Weintraub D (2012) Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 27(7):858–863PubMedCrossRef

19.

Kuzuhara S (2001) Drug-induced psychotic symptoms in Parkinson’s disease. Problems, management and dilemma. J Neurol 248 Suppl 3:III28–III31PubMedCrossRef

20.

Santangelo G, Trojano L, Vitale C, Ianniciello M, Amboni M, Grossi D et al (2007) A neuropsychological longitudinal study in Parkinson’s patients with and without hallucinations. Mov Disord 22(16):2418–2425PubMedCrossRef

21.

Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Bargallo N et al (2010) Differential progression of brain atrophy in Parkinson’s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 81(6):650–657PubMedCrossRef

22.

Tolosa E, Gaig C, Santamaria J, Compta Y (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology 72(7 Suppl):S12–S20PubMedCrossRef

23.

Myslobodsky M, Lalonde FM, Hicks L (2001) Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 14(3):120–124PubMedCrossRef

24.

Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49(4):381–389PubMedCrossRef

25.

Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125(Pt 2):391–403PubMedCrossRef

26.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM (2010) Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30(21):7281–7289PubMedCrossRef

27.

Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134(Pt 5):1493–1505PubMedCrossRef

28.

Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S et al (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26(4):343–350PubMedCrossRef

29.

Josephs KA, Whitwell JL, Parisi JE, Knopman DS, Boeve BF, Geda YE et al (2008) Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging 29(4):566–573PubMedCrossRef

30.

Buongiorno M, Compta Y, Marti MJ (2011) Amyloid-beta and tau biomarkers in Parkinson’s disease-dementia. J Neurol Sci 310(1–2):25–30PubMedCrossRef

Title: Prominent psychiatric symptoms in patients with Parkinson’s disease and concomitant argyrophilic grain disease
Authors: O. Grau-Rivera
E. Gelpi
M. J. Rey
F. Valldeoriola
E. Tolosa
Y. Compta
M. J. Martí
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 12/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-7101-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prominent psychiatric symptoms in patients with Parkinson’s disease and concomitant argyrophilic grain disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

Ultrasound of inherited vs. acquired demyelinating polyneuropathies

Endurance training in MS: short-term immune responses and their relation to cardiorespiratory fitness, health-related quality of life, and fatigue

The impact of guidelines on the quality of MRI diagnostics in adult patients referred to a tertiary Epilepsy Centre

Enhanced reticulospinal output in patients with (REEP1) hereditary spastic paraplegia type 31

Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients